Parkinson's Disease
Conditions
Brief summary
The Harvard Biomarker Study is a Harvard-wide, longitudinal case-control study designed for discovering, replicating, and developing biomarkers for Parkinson's disease and Alzheimer's disease. High-quality biosamples and high-resolution clinical phenotypes are tracked at three visits over a two-year period for more than 2,000 individuals with early-stage PD, MCI/AD, and controls without neurologic disease. The present Ancillary Longitudinal CSF Collection Study (short HBS2) is an ancillary study to the parent Harvard Biomarker Study. HBS2 is funded by the NINDS. In HBS2, 75 participants are more intensely studied and followed over a three-year time period. Clinical data and blood biospecimens are collected every six months and four annual CSF collections are performed. Biospecimens and clinical data are deposited into the NINDS PD Biomarkers Program (PDBP) Repository and the Data Management Resource (DMR) and are accessible through the PDBP DMR website.
Interventions
None listed
Sponsors
National Institute of Neurological Disorders and Stroke (NINDS)
Harvard Medical School (HMS and HSDM)
Brigham and Women's Hospital
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
21 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
for Cases with PD: * Age ≥ 21 * UK Parkinson's Disease Society Brain Bank criteria or movement disorder specialist diagnosis of PD * Hoehn & Yahr stage ≤ 3.0 * Mini Mental State Exam score \>21 OR authorized legal guardian available to sign consent * Able to provide informed consent Inclusion Criteria for Controls: * Age ≥ 21 * Absence of any neurological disease * No family history of a first-degree relative with PD * Mini Mental State Exam score \>21 OR authorized legal guardian available to sign consent * Able to provide informed consent
Exclusion criteria
for Cases and Controls: * Acquired or inherited bleeding disorders * Hematologic malignancies * Hematocrit \< 30 * Active ulcer or active colitis * Known pregnancy * Clinical contraindications to lumbar puncture (including: known mass lesion of the CNS or evidence for raised intracranial pressure on fundoscopic exam; abnormal coagulation tests; platelet count \< 50,000; subject on warfarin (coumadin), heparin, dabigatran, rivaroxiban or apixaban; subject on both aspirin and clopidogrel (Plavix); infection near the LP site or spinal deformity; known allergy to lidocaine)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean difference in the relative abundance of prioritized transcripts measured in CSF in the PD group compared to the healthy control group. | Enrollment visit |
Countries
United States
Outcome results
None listed